Classification
Compound class	Antibody

International Nonproprietary Names
INN number	INN
9878	bimekizumab

Synonyms

CA028_0496 | CDP4940 | gL7gH9 | UCB-4940 | UCB4940 | Zu-G1

Comments

Bimekizumab (UCB4940) is a rat-derived humanized Phase 2 monoclonal antibody targeting both IL-17A and IL-7F (dual antagonist), with potential for controlling autoimmune conditions mediated by these proinflammatory cytokines. Safety, pharmacokinetics and clinical efficacy of bimekizumab in mild psoriasis are reported in [2]. Claimed in patent WO2008047134 as CA028_0496 [1].

Database Links
Specialist databases
IMGT/mAb-DB	486
Other databases
GtoPdb PubChem SID	328083513
Search PubMed clinical trials	bimekizumab
Search PubMed titles	bimekizumab
Search PubMed titles/abstracts	bimekizumab